Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NATCO Pharma Limited ( (IN:NATCOPHARM) ) has issued an update.
Natco Pharma has clarified to the National Stock Exchange that its partnership with Eris Lifesciences for the weight-loss drug semaglutide follows the recent approval of the product by the Central Drugs Standard Control Organisation in India. The company said it is working with multiple marketing partners to launch semaglutide in March 2026 and characterized the Eris tie-up as part of its ordinary course of business with no material impact on operations.
Responding to the exchange’s surveillance query, Natco stated it is not aware of any undisclosed information that could explain trading movements in its shares. The company also noted that the media article on the Eris deal currently has no material financial impact and reiterated that it continues to comply with disclosure requirements under SEBI’s Listing Obligations and Disclosure Regulations.
More about NATCO Pharma Limited
Natco Pharma Limited is an India-based pharmaceutical company focused on developing, manufacturing, and marketing finished dosage formulations and active pharmaceutical ingredients. The company operates across domestic and international markets, with a portfolio that spans specialty therapeutics and complex generics, positioning it as a notable player in the broader healthcare and generics space.
Average Trading Volume: 146,651
Technical Sentiment Signal: Buy
Current Market Cap: 159.5B INR
For detailed information about NATCOPHARM stock, go to TipRanks’ Stock Analysis page.